US regulators give limited approval to cholesterol drug

July 25, 2015

US regulators on Friday approved a new cholesterol drug called Praluent, made by Sanofi and Regeneron, for people with certain genetic risk factors for heart disease.

The injectable drug is the first of its kind to gain approval on the US market, and offers an alternative to popular pill-based statins.

However, the US Food and Drug Administration approved it only for adults with an inherited condition that predisposes them to high cholesterol and raises the risk of heart attack and stroke.

"Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol," the FDA said in a statement.

HeFH is an inherited condition that causes high levels of the bad kind of cholesterol, known as low-density lipoprotein (LDL) .

Known also as alirocumab, the treatment is part of a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.

These drugs block the PCSK9 gene in the liver, which results in plummeting levels of LDL.

Explore further: US experts urge approval of another new cholesterol drug (Update)

Related Stories

US experts urge approval of another new cholesterol drug (Update)

June 10, 2015
US experts urged regulators Wednesday to approve a second new anti-cholesterol drug, a day after recommending they bring to market the first in a new class of medications to lower the risk of heart attack.

FDA weighs approval of first-in-class cholesterol drug

June 5, 2015
Federal health regulators said Friday that a highly-anticipated, experimental drug from Sanofi lowers bad cholesterol more than older drugs. But officials have questions about whether to approve the drug based on that measure ...

FDA panel backs first-in-class cholesterol drug

June 9, 2015
Federal health advisers on Tuesday recommended approval for a highly-anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with the caveat that more data is needed about its long-term ability to reduce ...

FDA panel backs Amgen cholesterol drug for some patients (Update)

June 10, 2015
Federal health advisers said Wednesday that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance.

Europe approves Amgen's first-in-class cholesterol drug

July 21, 2015
Amgen on Tuesday received European approval for its first-of-a-kind cholesterol drug that lowers levels of the artery-clogging substance more than older drugs that have been prescribed for decades.

New class of cholesterol drug proves safe and effective for patients with dyslipidemia

April 27, 2015
Treatment with PCSK9 antibodies reduces mortality and produces profound reductions in LDL-cholesterol and lipoprotein in patients with dyslipidemia. The results of this systematic review and meta-analysis are being published ...

Recommended for you

Complex inhalers prevent patients from taking medicine

February 23, 2018
Respiratory disease patients with arthritis could struggle to manage their conditions because their inhalers are too fiddly for them to use, University of Bath research has found.

Opioid abuse leads to heroin use and a hepatitis C epidemic, researcher says

February 22, 2018
Heroin is worse than other drugs because people inject it much sooner, potentially resulting in increased risk of injection-related epidemics such as hepatitis C and HIV, a Keck School of Medicine of USC study shows.

Opioid addiction treatment behind bars reduced post-incarceration overdose deaths in RI

February 14, 2018
A treatment program for opioid addiction launched by the Rhode Island Department of Corrections was associated with a significant drop in post-incarceration drug overdose deaths and contributed to an overall drop in overdose ...

Heroin vaccine blocks lethal overdose

February 14, 2018
Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug. Their research, published ...

Study shows NIH spent >$100 billion on basic science for new medicines

February 12, 2018
Federally funded research contributed to the science underlying all new medicines approved by the FDA over the past six years, according to a new study by Bentley University.

Opioid use increases risk of serious infections

February 12, 2018
Opioid users have a significantly increased risk of infections severe enough to require treatment at the hospital, such as pneumonia and meningitis, as compared to people who don't use opioids.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.